Literature DB >> 35730564

Biochemical, biophysical, and immunological characterization of respiratory secretions in severe SARS-CoV-2 infections.

Michael J Kratochvil1,2, Gernot Kaber1, Sally Demirdjian1, Pamela C Cai3, Elizabeth B Burgener4, Nadine Nagy1, Graham L Barlow1, Medeea Popescu1, Mark R Nicolls5, Michael G Ozawa6, Donald P Regula6, Ana E Pacheco-Navarro5, Samuel Yang7, Vinicio A de Jesus Perez5, Harry Karmouty-Quintana8,9, Andrew M Peters8, Bihong Zhao10,11, Maximilian L Buja10,11, Pamela Y Johnson12, Robert B Vernon12, Thomas N Wight12, Carlos E Milla4, Angela J Rogers5, Andrew J Spakowitz3, Sarah C Heilshorn2, Paul L Bollyky1.   

Abstract

Thick, viscous respiratory secretions are a major pathogenic feature of COVID-19, but the composition and physical properties of these secretions are poorly understood. We characterized the composition and rheological properties (i.e., resistance to flow) of respiratory secretions collected from intubated COVID-19 patients. We found the percentages of solids and protein content were greatly elevated in COVID-19 compared with heathy control samples and closely resembled levels seen in cystic fibrosis, a genetic disease known for thick, tenacious respiratory secretions. DNA and hyaluronan (HA) were major components of respiratory secretions in COVID-19 and were likewise abundant in cadaveric lung tissues from these patients. COVID-19 secretions exhibited heterogeneous rheological behaviors, with thicker samples showing increased sensitivity to DNase and hyaluronidase treatment. In histologic sections from these same patients, we observed increased accumulation of HA and the hyaladherin versican but reduced tumor necrosis factor-stimulated gene-6 staining, consistent with the inflammatory nature of these secretions. Finally, we observed diminished type I interferon and enhanced inflammatory cytokines in these secretions. Overall, our studies indicated that increases in HA and DNA in COVID-19 respiratory secretion samples correlated with enhanced inflammatory burden and suggested that DNA and HA may be viable therapeutic targets in COVID-19 infection.

Entities:  

Keywords:  COVID-19; Innate immunity; Pulmonology; Respiration

Mesh:

Substances:

Year:  2022        PMID: 35730564      PMCID: PMC9309048          DOI: 10.1172/jci.insight.152629

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  80 in total

1.  Roles of mucus adhesion and cohesion in cough clearance.

Authors:  Brian Button; Henry P Goodell; Eyad Atieh; Yu-Cheng Chen; Robert Williams; Siddharth Shenoy; Elijah Lackey; Nathan T Shenkute; Li-Heng Cai; Robert G Dennis; Richard C Boucher; Michael Rubinstein
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-12       Impact factor: 11.205

2.  Soluble CD40-ligand (sCD40L, sCD154) plays an immunosuppressive role via regulatory T cell expansion in HIV infection.

Authors:  M-A Jenabian; M Patel; I Kema; K Vyboh; C Kanagaratham; D Radzioch; P Thébault; R Lapointe; N Gilmore; P Ancuta; C Tremblay; J-P Routy
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

3.  Inflammation Profiling of Critically Ill Coronavirus Disease 2019 Patients.

Authors:  Douglas D Fraser; Gediminas Cepinskas; Marat Slessarev; Claudio Martin; Mark Daley; Michael R Miller; David B O'Gorman; Sean E Gill; Eric K Patterson; Claudia C Dos Santos
Journal:  Crit Care Explor       Date:  2020-06-22

4.  Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.

Authors:  H J Fuchs; D S Borowitz; D H Christiansen; E M Morris; M L Nash; B W Ramsey; B J Rosenstein; A L Smith; M E Wohl
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

5.  Mucolytics, expectorants, and mucokinetic medications.

Authors:  Bruce K Rubin
Journal:  Respir Care       Date:  2007-07       Impact factor: 2.258

Review 6.  Mucins, mucus, and sputum.

Authors:  Judith A Voynow; Bruce K Rubin
Journal:  Chest       Date:  2009-02       Impact factor: 9.410

Review 7.  Micro- and macrorheology of mucus.

Authors:  Samuel K Lai; Ying-Ying Wang; Denis Wirtz; Justin Hanes
Journal:  Adv Drug Deliv Rev       Date:  2009-01-03       Impact factor: 15.470

Review 8.  Mucins: the Old, the New and the Promising Factors in Hepatobiliary Carcinogenesis.

Authors:  Aldona Kasprzak; Agnieszka Adamek
Journal:  Int J Mol Sci       Date:  2019-03-14       Impact factor: 5.923

9.  COVID-19 Induced Acute Respiratory Distress Syndrome-A Multicenter Observational Study.

Authors:  Johannes Herrmann; Elisabeth Hannah Adam; Quirin Notz; Philipp Helmer; Michael Sonntagbauer; Peter Ungemach-Papenberg; Andreas Sanns; York Zausig; Thorsten Steinfeldt; Iuliu Torje; Benedikt Schmid; Tobias Schlesinger; Caroline Rolfes; Christian Reyher; Markus Kredel; Jan Stumpner; Alexander Brack; Thomas Wurmb; Daniel Gill-Schuster; Peter Kranke; Dirk Weismann; Hartwig Klinker; Peter Heuschmann; Viktoria Rücker; Stefan Frantz; Georg Ertl; Ralf Michael Muellenbach; Haitham Mutlak; Patrick Meybohm; Kai Zacharowski; Christopher Lotz
Journal:  Front Med (Lausanne)       Date:  2020-12-18

10.  Cytokine ranking via mutual information algorithm correlates cytokine profiles with presenting disease severity in patients infected with SARS-CoV-2.

Authors:  Kelsey E Huntington; Anna D Louie; Chun Geun Lee; Jack A Elias; Eric A Ross; Wafik S El-Deiry
Journal:  Elife       Date:  2021-01-14       Impact factor: 8.140

View more
  2 in total

1.  Ultraviolet dosage and decontamination efficacy were widely variable across 14 UV devices after testing a dried enveloped ribonucleic acid virus surrogate for SARS-CoV-2.

Authors:  Tony L Buhr; Erica Borgers-Klonkowski; Bradford W Gutting; Emlyn E Hammer; Shelia M Hamilton; Brett M Huhman; Stuart L Jackson; Neil L Kennihan; Samuel D Lilly; John D Little; Brooke B Luck; Emily A Matuczinski; Charles T Miller; Rachel E Sides; Vanessa L Yates; Alice A Young
Journal:  Front Bioeng Biotechnol       Date:  2022-10-04

Review 2.  Pathophysiological and Therapeutic Roles of Fascial Hyaluronan in Obesity-Related Myofascial Disease.

Authors:  Chiedozie Kenneth Ugwoke; Erika Cvetko; Nejc Umek
Journal:  Int J Mol Sci       Date:  2022-10-06       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.